Filing Details

Accession Number:
0001140361-14-005151
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-06 19:30:41
Reporting Period:
2014-02-04
Filing Date:
2014-02-06
Accepted Time:
2014-02-06 19:30:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1121404 Sanofi 54 Rue La Boetie
Paris I0 75008
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-04 1,264 $282.05 16,185,109 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-04 8,574 $283.17 16,193,683 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-04 12,946 $284.12 16,206,629 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-04 22,534 $285.08 16,229,163 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-04 36,795 $286.15 16,265,958 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-04 67,342 $287.18 16,333,300 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-04 40,831 $287.78 16,374,131 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 7,559 $274.64 16,381,690 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 6,775 $275.48 16,388,465 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 16,974 $276.53 16,405,439 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 15,530 $277.49 16,420,969 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 7,115 $278.54 16,428,084 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 2,983 $279.74 16,431,067 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 5,088 $280.96 16,436,155 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 18,605 $281.89 16,454,760 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 24,995 $282.85 16,479,755 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 45,362 $283.90 16,525,117 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 33,907 $284.97 16,559,024 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 16,173 $285.92 16,575,197 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 5,412 $286.78 16,580,609 No 4 P Indirect See note
Common Stock Acquisiton 2014-02-05 500 $288.13 16,581,109 No 4 P Indirect See note
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
Footnotes
  1. The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
  2. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
  3. Purchase prices range from $281.45 to $282.38 per share, inclusive.
  4. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 13,781,557 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuers Board of Directors.
  5. Purchase prices range from $282.50 to $283.48 per share, inclusive.
  6. Purchase prices range from $283.53 to $284.51 per share, inclusive
  7. Purchase prices range from $284.56 to $285.55 per share, inclusive.
  8. Purchase prices range from $285.59 to $286.58 per share, inclusive.
  9. Purchase prices range from $286.59 to $287.58 per share, inclusive.
  10. Purchase prices range from $287.59 to $288.26 per share, inclusive.
  11. Purchase prices range from $274.02 to $275.00 per share, inclusive.
  12. Purchase prices range from $275.03 to $276.02 per share, inclusive.
  13. Purchase prices range from $276.03 to $277.02 per share, inclusive.
  14. Purchase prices range from $277.03 to $278.02 per share, inclusive.
  15. Purchase prices range from $278.06 to $279.03 per share, inclusive.
  16. Purchase prices range from $279.23 to $280.22 per share, inclusive.
  17. Purchase prices range from $280.37 to $281.35 per share, inclusive.
  18. Purchase prices range from $281.39 to $282.36 per share, inclusive.
  19. Purchase prices range from $282.39 to $283.37 per share, inclusive.
  20. Purchase prices range from $283.41 to $284.37 per share, inclusive.
  21. Purchase prices range from $284.43 to $285.42 per share, inclusive.
  22. Purchase prices range from $285.46 to $286.26 per share, inclusive.
  23. Purchase prices range from $286.46 to $287.34 per share, inclusive.
  24. Purchase prices range from $287.47 to $288.30 per share, inclusive.